3B Future Health Fund

Profile and portfolio

Parent Helsinn GroupHQ Monaco, MonacoFounded 2016

3B Future Health Fund is the corporate venture arm of Helsinn Group, a pharmaceutical and biotech company. It was founded in 2016 and is based in Monaco, Monaco. It invests from seed to Series A. Sectors it names: biotech and life sciences.

Companies backedS1: 20+

Every figure links to its source

Snapshot

Investment stage: Seed to Series A

Data behind this graphic

Data behind this graphic
Item	Value
Stage range	Seed to Series A
Sectors	Biotech and life sciences
Geography	North America, Europe, Middle East and Africa
Offices	Monaco, Luxembourg

Sources: S1 3B Future Health Fund.

Scale and capital allocated

Data behind this graphic

Data behind this graphic
Measure	Value	Unit	Kind	Source
Companies backed	20+	companies	Stated by the firm	S1
Companies on the firm's portfolio page	20	companies	Counted from the firm's own list	S5

Sources: S1 3B Future Health Fund; S5 3B Future Health Fund portfolio.

Where it invests and who leads it

Geography

Headquarters: Monaco, Monaco
Offices: Monaco
Luxembourg

Investment regionsS1

LeadersS4

Riccardo BragliaChairman and General PartnerFind on LinkedIn Firm page
Alessandro SantoboniManaging Director and General PartnerFind on LinkedIn Firm page
Roberto De PontiGeneral PartnerFind on LinkedIn Firm page
Francesco GiavattoChief Financial Officer and General PartnerFind on LinkedIn Firm page
Marianne BjordalGeneral PartnerFind on LinkedIn Firm page

3B Future Health Fund on LinkedIn

Key facts

Fact	Value	Status	Source
Parent company	Helsinn Group	Single source	S2
Parent industry	Pharmaceuticals and biotech	Single source	S2
Founded	2016	Single source	S2
Headquarters	Monaco, Monaco	Single source	S3
Status	Active	Single source	S1
Capital source	Parent and outside investors	Single source	S2
Companies backed	20+	Single source	S1
Stages	Seed, Series A (inferred from announced rounds)	Estimate	S1

For founders

Item	What the firm says	Source
Stages	Seed, Series A. Inferred from announced rounds; the firm does not state a range.	S1
Pitch page	3bfuturehealth.com/contact/	S1

Portfolio

The firm's portfolio page lists 20 companies.S5

Shared portfolio with other corporate VCs

5 companies on the 3B Future Health Fund portfolio page also appear on the portfolio page of at least one other firm in this directory. Matched by company website, or by name where no website is published.

Firm	Shared	Companies in common
Astellas Venture Management	1	NeoPhore
Neva SGR	1	NeoPhore
Boehringer Ingelheim Venture Fund	1	AMAL Therapeutics
Novartis Venture Fund	1	Epsilogen
M Ventures	1	iOnctura
Olympus Innovation Ventures	1	On Target Laboratories

Companies backed by the most corporate VCs

Every company on the 3B Future Health Fund list

20 companies, as listed on the firm's own website.S5 Read the firm's list.

Aadi Bioscience
AMAL Therapeutics
Anacardio
Domain Therapeutics
Epsilogen
GAIN Therapeutics
Geneos Therapeutics
Greenbone Ortho
iOnctura
Kither Biotech
MEI Pharma
NeoPhore
Novellus
On Target Laboratories
OncoResponse
Personal Genome Diagnostics
QuantumDx
Roca Therapeutics
Sibylla Biotech
Utility Therapeutics

Notable outcomes

IPOs and acquisitions of portfolio companies. Price shown only where published.

Company	Type	Year	Source
AMAL Therapeutics	Acquisition	2019	S2

History

2016Fund launched by Helsinn executive chairman Riccardo BragliaS2
2019First exit: AMAL Therapeutics acquired for EUR 425mS2
2020Re-branded 3B Future Health Fund focused on oncology and rare diseaseS2

Official pages

Read the firm's own pages for current information.

Website 3bfuturehealth.com/
Portfolio 3bfuturehealth.com/companies/
Pitch page 3bfuturehealth.com/contact/

Sources

Disclaimer and corrections

Not affiliated. This page is not affiliated with, endorsed by or sponsored by 3B Future Health Fund or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.

Spotted a mistake? Report a correction.

Report a correction